Get the Stockscreener App
7.84
3.07%
0.22
Cadrenal Therapeutics Inc stock is traded at $7.84, with a volume of 31,108.
It is up +3.07% in the last 24 hours and up +5.99% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$7.62
Open:
$7.85
24h Volume:
31,108
Relative Volume:
0.63
Market Cap:
$18.45M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-25.29
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
+10.46%
1M Performance:
+5.99%
6M Performance:
-32.18%
1Y Performance:
-58.62%
1-Day Range:
$7.50
$7.96
1-Week Range:
$7.0701
$8.21
52-Week Range:
$6.42
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
7.89 | 17.82M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.38 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
757.42 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
845.68 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.94 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.98 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
(CVKD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Aug Momentum: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedMarket Volume Summary & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Why is Cadrenal Therapeutics stock drawing retail attention today? - MSN
Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today? - Stocktwits
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial - Intellectia AI
(CVKD) Risk Channels and Responsive Allocation - Stock Traders Daily
CVKD: VLX-1005 and Tecarfarin lead a strategy to address unmet needs in rare anticoagulation markets - TradingView — Track All Markets
CVKD: VLX-1005 and tecarfarin drive innovation in underserved anticoagulation markets, with key milestones ahead - TradingView — Track All Markets
Trend Report: Can GMGI stock double in the next yearJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Income Plays: Is Cadrenal Therapeutics Incs ROIC above industry averageEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder By Investing.com - Investing.com Nigeria
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder - Investing.com
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX In - GlobeNewswire
Cadrenal Therapeutics, Inc. - MSN
Will Cadrenal Therapeutics Inc. stock keep outperforming rivals2025 Key Highlights & Community Verified Watchlist Alerts - Улправда
Will Cadrenal Therapeutics Inc. stock benefit from commodity pricesWeekly Trend Summary & Real-Time Volume Trigger Notifications - Улправда
Can Cadrenal Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда
What sentiment indicators say about Cadrenal Therapeutics Inc. stockMarket Growth Report & Weekly Market Pulse Updates - Улправда
Risk Analysis: Why Cadrenal Therapeutics Inc. stock remains undervaluedBreakout Watch & Daily Profit Maximizing Tips - ulpravda.ru
How Cadrenal Therapeutics Inc. stock trades during market volatilityJuly 2025 Institutional & Stepwise Trade Execution Plans - Улправда
Is Cadrenal Therapeutics Inc. stock a contrarian buyTrade Performance Summary & Step-by-Step Swing Trade Plans - Улправда
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail
How a small biotech is building an emergency anticoagulation plan - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire
Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail
Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World
Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Cadrenal Therapeutics Inc. stock recession proofWeekly Profit Recap & Capital Efficient Trading Techniques - Улправда
Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Buying & Community Verified Trade Signals - Улправда
Can Cadrenal Therapeutics Inc. stock resist market sell offsJuly 2025 Movers & Technical Buy Zone Confirmations - Улправда
Can Cadrenal Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Summary & Daily Entry Point Trade Alerts - Улправда
Aug PreEarnings: Is Cadrenal Therapeutics Inc. stock a contrarian buy2025 Market Sentiment & Weekly High Momentum Picks - DonanımHaber
Ideas Watch: Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Selling & Weekly Setup with ROI Potential - Улправда
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - Улправда
How Cadrenal Therapeutics Inc. stock responds to policy changes2025 Bull vs Bear & Expert Curated Trade Setups - Улправда
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Volume & Technical Pattern Based Signals - Улправда
Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com
Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets
Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):